DRCR.net Protocol S: Lucentis noninferior to panretinal photocoagulation for visual acuity

LAS VEGAS — Ranibizumab is noninferior to panretinal photocoagulation with regard to visual acuity outcomes at 2 years in patients with proliferative diabetic retinopathy, according to a study presented here.“Lucentis (ranibizumab, Genentech) should be considered a viable treatment option for people with proliferative diabetic retinopathy, especially for individuals needing anti-VEGF for diabetic macular edema,” Jeffrey G. Gross, MD, said at the American Academy of Ophthalmology annual meeting.